HeartSciences Secures FDA 510(k) Clearance for MyoVista wavECG Device
HSCS has more than doubled off its 52-week low of $1.63 on elevated volume (3.9× avg).
Summary
HeartSciences received FDA 510(k) clearance for its MyoVista wavECG device as a 12-lead resting electrocardiograph, though the company says it will not commercialize the device without a separately cleared AI-ECG algorithm.
Key Events · Product Development and Regulatory · HSCS
-
FDA 510(k) Clearance Granted
The FDA granted 510(k) clearance (K260005) for the MyoVista wavECG device as a 12-lead resting electrocardiograph, covering ECG signal acquisition and interpretation for adult and pediatric patients in hospitals and healthcare facilities.
-
No AI-ECG Algorithm Included
The clearance does not include an AI-ECG algorithm. The company separated FDA submissions for the device and its impaired cardiac relaxation AI-ECG algorithm following updated ASE guidance.
-
No Commercialization Timeline
HeartSciences does not intend to commercialize the device without a cleared AI-ECG algorithm and has made no commitment to, and has no timeline for, commercialization.
-
Merger Context
The clearance comes amid the pending all-stock merger with Fortitude Mining, expected to close in Q4 2026 subject to shareholder approval. The company says the clearance broadens potential options for the device and its related intellectual property.
Analysis · HSCS · Crypto Assets
The FDA has granted 510(k) clearance to HeartSciences for its MyoVista wavECG device as a 12-lead resting electrocardiograph. This clearance validates the device's core hardware and signal acquisition, but the company explicitly states it will not commercialize the device without a separately cleared AI-ECG algorithm — and no timeline exists for that algorithm. Against the backdrop of a pending all-stock merger with Fortitude Mining that would leave existing shareholders with only 5% of the combined company, this clearance makes the device and its intellectual property a more readily realizable asset, potentially strengthening HeartSciences' negotiating position or the value of the legacy business being folded into the merger.
How filings like this one have moved
In the 30 days to Oct 6, 2026, 28.9% of the 1573 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HSCS was trading at $3.77 on NASDAQ in the Crypto Assets sector, with a market capitalization of approximately $18.3M. The 52-week trading range was $1.63 to $5.25. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.